CARsgen Therapeutics Co. Ltd. logo

CARsgen Therapeutics Co. Ltd.

CARsgen Therapeutics, is focused on the development of CAR-T-based autologous immunotherapy utilizing its proprietary immunotherapy technology to fight against solid tumors.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.carsgen.com
Disease Focus
STOCK CODENon Listed
Address
388 Yindu Road, Building B
Shanghai
China
Email
Contact Number
+86-21-64501828

CARsgen Therapeutics, is focused on the development of CAR-T-based autologous immunotherapy utilizing its proprietary immunotherapy technology to fight against solid tumors.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/carsgen-therapeutics” connections=”true” suffix=””]

CARsgen is using chimeric antigen receptor T-cells (CAR-T) targeting the Epidermal Growth Factor Receptor (EGFR) for the treatment of glioblastoma (the most malignant type of brain cancer).

In Oct 2015, CARsgen entered into a five year research and development partnership agreement with Shanghai Cancer Institute to develop novel CAR-T Technology.

In Jan 2016, CARsgen completed $30 Mn Series B private financing led by KTB Ventures, Jolly Innovation Ventures, Kaitai Capital and JIC Genesis Fountain Healthcare Ventures.